Literature DB >> 25225605

Apoptosis induced by Fas signaling does not alter hepatic hepcidin expression.

Sizhao Lu1, Emily Zmijewski1, John Gollan1, Duygu Dee Harrison-Findik1.   

Abstract

AIM: To determine the regulation of human hepcidin (HAMP) and mouse hepcidin (hepcidin-1 and hepcidin-2) gene expression in the liver by apoptosis using in vivo and in vitro experimental models.
METHODS: For the induction of the extrinsic apoptotic pathway, HepG2 cells were treated with various concentrations of CH11, an activating antibody for human Fas receptor, for 12 h. Male C57BL/6NCR and C57BL/6J strains of mice were injected intraperitoneally with sublethal doses of an activating antibody for mouse Fas receptor, Jo2. The mice were anesthetized and sacrificed 1 or 6 h after the injection. The level of apoptosis was quantified by caspase-3 activity assay. Liver injury was assessed by measuring the levels of ALT/AST enzymes in the serum. The acute phase reaction in the liver was examined by determining the expression levels of IL-6 and SAA3 genes by SYBR green quantitative real-time PCR (qPCR). The phosphorylation of transcription factors, Stat3, Smad4 and NF-κB was determined by western blotting. Hepcidin gene expression was determined by Taqman qPCR. The binding of transcription factors to hepcidin-1 promoter was studied using chromatin immunoprecipitation (ChIP) assays.
RESULTS: The treatment of HepG2 cells with CH11 induced apoptosis, as shown by the significant activation of caspase-3 (P < 0.001), but did not cause any significant changes in HAMP expression. Short-term (1 h) Jo2 treatment (0.2 μg/g b.w.) neither induced apoptosis and acute phase reaction nor altered mRNA expression of mouse hepcidin-1 in the livers of C57BL/6NCR mice. In contrast, 6 h after Jo2 injection, the livers of C57BL/6NCR mice exhibited a significant level of apoptosis (P < 0.001) and an increase in SAA3 (P < 0.023) and IL-6 (P < 0.005) expression in the liver. However, mRNA expression of hepcidin-1 in the liver was not significantly altered. Despite the Jo2-induced phosphorylation of Stat3, no occupancy of hepcidin-1 promoter by Stat3 was observed, as shown by ChIP assays. Compared to C57BL/6NCR mice, Jo2 treatment (0.2 μg/g b.w.) of C57BL/6J strain mice for 6 h induced a more prominent activation of apoptosis, liver injury and acute phase reaction. Similar to C57BL/6NCR mice, the level of liver hepcidin-1 mRNA expression in the livers of C57BL/6J mice injected with a sublethal dose of Jo2 (0.2 μg/g b.w.) remained unchanged. The injection of C57BL/6J mice with a higher dose of Jo2 (0.32 μg/g b.w.) did not also alter hepatic hepcidin expression.
CONCLUSION: Our findings suggest that human or mouse hepcidin gene expression is not regulated by apoptosis induced via Fas receptor activation in the liver.

Entities:  

Keywords:  CH11; Extrinsic apoptosis; Iron metabolism; Jo2; Stat3

Year:  2014        PMID: 25225605      PMCID: PMC4160531          DOI: 10.4331/wjbc.v5.i3.387

Source DB:  PubMed          Journal:  World J Biol Chem        ISSN: 1949-8454


  33 in total

1.  The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury.

Authors:  Shiho Natori; Hajime Higuchi; Patricia Contreras; Gregory J Gores
Journal:  Liver Transpl       Date:  2003-03       Impact factor: 5.799

2.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

3.  Serum-induced up-regulation of hepcidin expression involves the bone morphogenetic protein signaling pathway.

Authors:  Nanda Kumar N Shanmugam; Bobby J Cherayil
Journal:  Biochem Biophys Res Commun       Date:  2013-10-21       Impact factor: 3.575

4.  Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.

Authors:  Jodie L Babitt; Franklin W Huang; Diedra M Wrighting; Yin Xia; Yisrael Sidis; Tarek A Samad; Jason A Campagna; Raymond T Chung; Alan L Schneyer; Clifford J Woolf; Nancy C Andrews; Herbert Y Lin
Journal:  Nat Genet       Date:  2006-04-09       Impact factor: 38.330

5.  Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol.

Authors:  Duygu Dee Harrison-Findik; Elizabeth Klein; Callie Crist; John Evans; Nikolai Timchenko; John Gollan
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

6.  Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin.

Authors:  Xiang Li; Feng Xu; Ekapun Karoopongse; A Mario Marcondes; Kayoung Lee; Kris V Kowdley; Carol H Miao; Grant D Trobridge; Jean S Campbell; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2013-05-22       Impact factor: 5.742

7.  Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53.

Authors:  Orly Weizer-Stern; Konstantin Adamsky; Ofer Margalit; Osnat Ashur-Fabian; David Givol; Ninette Amariglio; Gideon Rechavi
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

8.  Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms.

Authors:  Sanae Haga; Keita Terui; Hui Qi Zhang; Shin Enosawa; Wataru Ogawa; Hiroshi Inoue; Torayuki Okuyama; Kiyoshi Takeda; Shizuo Akira; Tetsuya Ogino; Kaikobad Irani; Michitaka Ozaki
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4.

Authors:  Lan Lin; Erika V Valore; Elizabeta Nemeth; Julia B Goodnough; Victoria Gabayan; Tomas Ganz
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

10.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.

Authors:  Antonello Pietrangelo; Uta Dierssen; Linda Valli; Cinzia Garuti; Agrani Rump; Elena Corradini; Matthias Ernst; Christian Klein; Christian Trautwein
Journal:  Gastroenterology       Date:  2006-10-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.